Discovery and Characterization of 2-Anilino-4-(Thiazol-5-yl)Pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents

被引:93
作者
Wang, Shudong [1 ]
Griffiths, Gary [1 ]
Midgley, Carol A. [1 ]
Barnett, Anna L. [1 ]
Cooper, Michael [1 ]
Grabarek, Joanna [1 ]
Ingram, Laura [1 ]
Jackson, Wayne [1 ]
Kontopidis, George [1 ]
McClue, Steven J. [1 ]
McInnes, Campbell [1 ]
McLachlan, Janice [1 ]
Meades, Christopher [1 ]
Mezna, Mokdad [1 ]
Stuart, Iain [1 ]
Thomas, Mark P. [1 ]
Zheleva, Daniella I. [1 ]
Lane, David P. [1 ]
Jackson, Robert C. [1 ]
Glover, David M. [1 ]
Blake, David G. [1 ]
Fischer, Peter M. [1 ]
机构
[1] Cyclacel Ltd, Dundee DD1 5JJ, Scotland
来源
CHEMISTRY & BIOLOGY | 2010年 / 17卷 / 10期
关键词
RNA-POLYMERASE-II; DEPENDENT KINASE INHIBITOR; CHRONIC LYMPHOCYTIC-LEUKEMIA; CARBOXYL-TERMINAL DOMAIN; P-TEFB; BIOLOGICAL-ACTIVITY; APOPTOSIS PROTEINS; P53; FLAVOPIRIDOL; CELLS;
D O I
10.1016/j.chembiol.2010.07.016
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The main difficulty in the development of ATP antagonist kinase inhibitors is target specificity, since the ATP-binding motif is present in many proteins We introduce a strategy that has allowed us to identify compounds from a kinase inhibitor library that block the cyclin-dependent kinases responsible for regulating transcription, i e, CDK7 and especially CDK9 The screening cascade employs cellular phenotypic assays based on mitotic index and nuclear p53 protein accumulation This permitted us to classify compounds into transcriptional, cell cycle, and mitotic inhibitor groups We describe the charaterization of the transcriptional inhibitor class in terms of kinase inhibition profile, cellular mode of action, and selectivity for transformed cells A structural selectivity rationale was used to optimize potency and biopharmaceutical properties and led to the development of a transcriptional inhibitor, 3,4-dimethyl-5[2-(4-piperazin-1-yl-phenylamino)-pyrimidin-4-yl]-3H-thiazol-2-one, with anticancer activity in animal models
引用
收藏
页码:1111 / 1121
页数:11
相关论文
共 50 条
[1]   Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria [J].
Arima, Y ;
Nitta, M ;
Kuninaka, S ;
Zhang, DW ;
Fujiwara, T ;
Taya, Y ;
Nakao, M ;
Saya, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (19) :19166-19176
[2]   Mice thrive without Cdk4 and Cdk2 [J].
Barriere, Cedric ;
Santamaria, David ;
Cerqueira, Antonio ;
Galan, Javier ;
Martin, Alberto ;
Ortega, Sagrario ;
Malumbres, Marcos ;
Dubus, Pierre ;
Barbacid, Mariano .
MOLECULAR ONCOLOGY, 2007, 1 (01) :72-83
[3]   The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation [J].
Baumli, Sonja ;
Lolli, Graziano ;
Lowe, Edward D. ;
Troiani, Sonia ;
Rusconi, Luisa ;
Bullock, Alex N. ;
Debreczeni, Judit E. ;
Knapp, Stefan ;
Johnson, Louise N. .
EMBO JOURNAL, 2008, 27 (13) :1907-1918
[4]   The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases [J].
Brown, NR ;
Noble, MEM ;
Endicott, JA ;
Johnson, LN .
NATURE CELL BIOLOGY, 1999, 1 (07) :438-443
[5]   Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia [J].
Byrd, John C. ;
Lin, Thomas S. ;
Dalton, James T. ;
Wu, Di ;
Phelps, Mitch A. ;
Fischer, Beth ;
Moran, Mollie ;
Blum, Kristie A. ;
Rovin, Brad ;
Brooker-McEldowney, Michelle ;
Broering, Sarah ;
Schaaf, Larry J. ;
Johnson, Amy J. ;
Lucas, David M. ;
Heerema, Nyla A. ;
Lozanski, Gerard ;
Young, Donn C. ;
Suarez, Jose-Ramon ;
Colevas, A. Dimitrios ;
Grever, Michael R. .
BLOOD, 2007, 109 (02) :399-404
[6]   Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death [J].
Chen, R ;
Keating, MJ ;
Gandhi, V ;
Plunkett, W .
BLOOD, 2005, 106 (07) :2513-2519
[7]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[8]   The Bcl-2 family: roles in cell survival and oncogenesis [J].
Cory, S ;
Huang, DCS ;
Adams, JM .
ONCOGENE, 2003, 22 (53) :8590-8607
[9]   Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor [J].
Demidenko, ZN ;
Blagosklonny, MV .
CANCER RESEARCH, 2004, 64 (10) :3653-3660
[10]   Recent progress in the discovery and development of cyclin-dependant kinase inhibitors [J].
Fischer, PM ;
Gianella-Borradori, A .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (04) :457-477